| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Abe, O, et al.
(författare)
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
- 2005
-
Ingår i: The Lancet. - 1474-547X. ; 365:9472, s. 1687-1717
-
Tidskriftsartikel (refereegranskat)abstract
- Background Quinquennial overviews (1985-2000) of the randomised trials in early breast cancer have assessed the 5-year and 10-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival. Here, we report the 10-year and 15-year effects. Methods Collaborative meta-analyses were undertaken of 194 unconfounded randomised trials of adjuvant chemotherapy or hormonal therapy that began by 1995. Many trials involved CMF (cyclophosphamide, methotrexate, fluorouracil), anthracycline-based combinations such as FAC (fluorouracil, doxombicin, cyclophosphamide) or FEC (fluorouracil, epirubicin, cyclophosphamide), tamoxifen, or ovarian suppression: none involved taxanes, trastuzumab, raloxifene, or modem aromatase inhibitors. Findings Allocation to about 6 months of anthracycline-based polychemotherapy (eg, with FAC or FEC) reduces the annual breast cancer death rate by about 38% (SE 5) for women younger than 50 years of age when diagnosed and by about 20% (SE 4) for those of age 50-69 years when diagnosed, largely irrespective of the use of tamoxifen and of oestrogen receptor (ER) status, nodal status, or other tumour characteristics. Such regimens are significantly (2p=0 . 0001 for recurrence, 2p<0 . 00001 for breast cancer mortality) more effective than CMF chemotherapy. Few women of age 70 years or older entered these chemotherapy trials. For ER-positive disease only, allocation to about 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31% (SE 3), largely irrespective of the use of chemotherapy and of age (<50, 50-69, &GE; 70 years), progesterone receptor status, or other tumour characteristics. 5 years is significantly (2p<0 . 00001 for recurrence, 2p=0 . 01 for breast cancer mortality) more effective than just 1-2 years of tamoxifen. For ER-positive tumours, the annual breast cancer mortality rates are similar during years 0-4 and 5-14, as are the proportional reductions in them by 5 years of tamoxifen, so the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis. These results combine six meta-analyses: anthracycline-based versus no chemotherapy (8000 women); CMF-based versus no chemotherapy (14 000); anthracycline-based versus CMF-based chemotherapy (14 000); about 5 years of tamoxifen versus none (15 000); about 1-2 years of tamoxifen versus none (33 000); and about 5 years versus 1-2 years of tamoxifen (18 000). Finally, allocation to ovarian ablation or suppression (8000 women) also significantly reduces breast cancer mortality, but appears to do so only in the absence of other systemic treatments. For middle-aged women with ER-positive disease (the commonest type of breast cancer), the breast cancer mortality rate throughout the next 15 years would be approximately halved by 6 months of anthracycline-based chemotherapy (with a combination such as FAC or FEC) followed by 5 years of adjuvant tamoxifen. For, if mortality reductions of 38% (age <50 years) and 20% (age 50-69 years) from such chemotherapy were followed by a further reduction of 31% from tamoxifen in the risks that remain, the final mortality reductions would be 57% and 45%, respectively (and, the trial results could well have been somewhat stronger if there had been full compliance with the allocated treatments). Overall survival would be comparably improved, since these treatments have relatively small effects on mortality from the aggregate of all other causes. Interpretation Some of the widely practicable adjuvant drug treatments that were being tested in the 1980s, which substantially reduced 5-year recurrence rates (but had somewhat less effect on 5-year mortality rates), also substantially reduce 15-year mortality rates. Further improvements in long-term survival could well be available from newer drugs, or better use of older drugs.
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
| 11. |
|
|
| 12. |
|
|
| 13. |
- Wagner, J., et al.
(författare)
-
First 230? : GHz VLBI fringes on 3C 279 using the APEX Telescope (Research Note)
- 2015
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 581
-
Tidskriftsartikel (refereegranskat)abstract
- Aims. We report about a 230? GHz very long baseline interferometry (VLBI) fringe finder observation of blazar 3C 279 with the APEX telescope in Chile, the phased submillimeter array (SMA), and the SMT of the Arizona Radio Observatory (ARO). Methods. We installed VLBI equipment and measured the APEX station position to 1? cm accuracy (1σ). We then observed 3C 279 on 2012 May 7 in a 5? h 230? GHz VLBI track with baseline lengths of 2800? Mλ to 7200? Mλ and a finest fringe spacing of 28.6? μas. Results. Fringes were detected on all baselines with signal-to-noise ratios of 12 to 55 in 420? s. The correlated flux density on the longest baseline was ∼0.3? Jy beam-1, out of a total flux density of 19.8? Jy. Visibility data suggest an emission region ≤ 38? μas in size, and at least two components, possibly polarized. We find a lower limit of the brightness temperature of the inner jet region of about 1010? K. Lastly, we find an upper limit of 20% on the linear polarization fraction at a fringe spacing of ∼ 38? μas. Conclusions. With APEX the angular resolution of 230? GHz VLBI improves to 28.6? μas. This allows one to resolve the last-photon ring around the Galactic Center black hole event horizon, expected to be 40? μas in diameter, and probe radio jet launching at unprecedented resolution, down to a few gravitational radii in galaxies like M 87. To probe the structure in the inner parsecs of 3C 279 in detail, follow-up observations with APEX and five other mm-VLBI stations have been conducted (March 2013) and are being analyzed.
|
|
| 14. |
- Geisler, D., et al.
(författare)
-
CAPOS : The bulge Cluster APOgee Survey I. Overview and initial ASPCAP results
- 2021
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 652
-
Tidskriftsartikel (refereegranskat)abstract
- Context. Bulge globular clusters (BGCs) are exceptional tracers of the formation and chemodynamical evolution of this oldest Galactic component. However, until now, observational difficulties have prevented us from taking full advantage of these powerful Galactic archeological tools. Aims. CAPOS, the bulge Cluster APOgee Survey, addresses this key topic by observing a large number of BGCs, most of which have only been poorly studied previously. Even their most basic parameters, such as metallicity, [alpha/Fe], and radial velocity, are generally very uncertain. We aim to obtain accurate mean values for these parameters, as well as abundances for a number of other elements, and explore multiple populations. In this first paper, we describe the CAPOS project and present initial results for seven BGCs. Methods. CAPOS uses the APOGEE-2S spectrograph observing in the H band to penetrate obscuring dust toward the bulge. For this initial paper, we use abundances derived from ASPCAP, the APOGEE pipeline. Results. We derive mean [Fe/H] values of -0.85 +/- 0.04 (Terzan 2), -1.40 +/- 0.05 (Terzan 4), -1.20 +/- 0.10 (HP 1), -1.40 +/- 0.07 (Terzan 9), -1.07 +/- 0.09 (Djorg 2), -1.06 +/- 0.06 (NGC 6540), and -1.11 +/- 0.04 (NGC 6642) from three to ten stars per cluster. We determine mean abundances for eleven other elements plus the mean [alpha/Fe] and radial velocity. CAPOS clusters significantly increase the sample of well-studied Main Bulge globular clusters (GCs) and also extend them to lower metallicity. We reinforce the finding that Main Bulge and Main Disk GCs, formed in situ, have [Si/Fe] abundances slightly higher than their accreted counterparts at the same metallicity. We investigate multiple populations and find our clusters generally follow the light-element (anti)correlation trends of previous studies of GCs of similar metallicity. We finally explore the abundances of the iron-peak elements Mn and Ni and compare their trends with field populations. Conclusions. CAPOS is proving to be an unprecedented resource for greatly improving our knowledge of the formation and evolution of BGCs and the bulge itself.
|
|
| 15. |
|
|
| 16. |
|
|
| 17. |
- Burdett, S., et al.
(författare)
-
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer
- 2015
-
Ingår i: Cochrane Database of Systematic Reviews. - 1469-493X. ; :3
-
Forskningsöversikt (refereegranskat)abstract
- Background To evaluate the effects of administering chemotherapy following surgery, or following surgery plus radiotherapy (known as adjuvant chemotherapy) in patients with early stage non-small cell lung cancer (NSCLC), we performed two systematic reviews andmeta-analyses of all randomised controlled trials using individual participant data. Results were first published in The Lancet in 2010. Objectives To compare, in terms of overall survival, time to locoregional recurrence, time to distant recurrence and recurrence-free survival: A. Surgery versus surgery plus adjuvant chemotherapy B. Surgery plus radiotherapy versus surgery plus radiotherapy plus adjuvant chemotherapy in patients with histologically diagnosed early stage NSCLC. (2) To investigate whether or not predefined patient subgroups benefit more or less from cisplatin-based chemotherapy in terms of survival. Search methods We supplemented MEDLINE and CANCERLIT searches (1995 to December 2013) with information from trial registers, hand-searching relevant meeting proceedings and by discussion with trialists and organisations. Selection criteria We included trials of a) surgery versus surgery plus adjuvant chemotherapy; and b) surgery plus radiotherapy versus surgery plus radiotherapy plus adjuvant chemotherapy, provided that they randomised NSCLC patients using a method which precluded prior knowledge of treatment assignment. Data collection and analysis We carried out a quantitative meta-analysis using updated information from individual participants from all randomised trials. Data from all patients were sought from those responsible for the trial. We obtained updated individual participant data (IPD) on survival, and date of last follow-up, as well as details of treatment allocated, date of randomisation, age, sex, histological cell type, stage, and performance status. To avoid potential bias, we requested information for all randomised patients, including those excluded from the investigators' original analyses. We conducted all analyses on intention-to-treat on the endpoint of survival. For trials using cisplatin-based regimens, we carried out subgroup analyses by age, sex, histological cell type, tumour stage, and performance status. Main results We identified 35 trials evaluating surgery plus adjuvant chemotherapy versus surgery alone. IPD were available for 26 of these trials and our analyses are based on 8447 participants (3323 deaths) in 34 trial comparisons. There was clear evidence of a benefit of adding chemotherapy after surgery (hazard ratio (HR)= 0.86, 95% confidence interval (CI)= 0.81 to 0.92, p< 0.0001), with an absolute increase in survival of 4% at five years. We identified 15 trials evaluating surgery plus radiotherapy plus chemotherapy versus surgery plus radiotherapy alone. IPD were available for 12 of these trials and our analyses are based on 2660 participants (1909 deaths) in 13 trial comparisons. There was also evidence of a benefit of adding chemotherapy to surgery plus radiotherapy (HR= 0.88, 95% CI= 0.81 to 0.97, p= 0.009). This represents an absolute improvement in survival of 4% at five years. For both meta-analyses, we found similar benefits for recurrence outcomes and there was little variation in effect according to the type of chemotherapy, other trial characteristics or patient subgroup. We did not undertake analysis of the effects of adjuvant chemotherapy on quality of life and adverse events. Quality of life information was not routinely collected during the trials, but where toxicity was assessed and mentioned in the publications, it was thought to be manageable. We considered the risk of bias in the included trials to be low. Authors' conclusions Results from 47 trial comparisons and 11,107 patients demonstrate the clear benefit of adjuvant chemotherapy for these patients, irrespective of whether chemotherapy was given in addition to surgery or surgery plus radiotherapy. This is the most up-to-date and complete systematic review and individual participant data (IPD) meta-analysis that has been carried out.
|
|
| 18. |
|
|
| 19. |
- Roy, Alan, et al.
(författare)
-
VLBI at APEX: First Fringes
- 2012
-
Ingår i: Proceedings of Science. - 1824-8039. ; 2012-October
-
Konferensbidrag (refereegranskat)
|
|
| 20. |
- Santana, Felipe A., et al.
(författare)
-
Final Targeting Strategy for the SDSS-IV APOGEE-2S Survey
- 2021
-
Ingår i: Astronomical Journal. - : American Astronomical Society. - 1538-3881 .- 0004-6256. ; 162:6
-
Tidskriftsartikel (refereegranskat)abstract
- APOGEE is a high-resolution (R similar to 22,000), near-infrared, multi-epoch, spectroscopic survey of the Milky Way. The second generation of the APOGEE project, APOGEE-2, includes an expansion of the survey to the Southern Hemisphere called APOGEE-2S. This expansion enabled APOGEE to perform a fully panoramic mapping of all of the main regions of the Milky Way; in particular, by operating in the H band, APOGEE is uniquely able to probe the dust-hidden inner regions of the Milky Way that are best accessed from the Southern Hemisphere. In this paper we present the targeting strategy of APOGEE-2S, with special attention to documenting modifications to the original, previously published plan. The motivation for these changes is explained as well as an assessment of their effectiveness in achieving their intended scientific objective. In anticipation of this being the last paper detailing APOGEE targeting, we present an accounting of all such information complete through the end of the APOGEE-2S project; this includes several main survey programs dedicated to exploration of major stellar populations and regions of the Milky Way, as well as a full list of programs contributing to the APOGEE database through allocations of observing time by the Chilean National Time Allocation Committee and the Carnegie Institution for Science. This work was presented along with a companion article, Beaton et al. (2021), presenting the final target selection strategy adopted for APOGEE-2 in the Northern Hemisphere.
|
|
| 21. |
|
|
| 22. |
|
|
| 23. |
|
|
| 24. |
- Schultheis, M., et al.
(författare)
-
Baade's window and APOGEE Metallicities, ages, and chemical abundances
- 2017
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 600
-
Tidskriftsartikel (refereegranskat)abstract
- Context. Baade's window (BW) is one of the most observed Galactic bulge fields in terms of chemical abundances. Owing to its low and homogeneous interstellar absorption it is considered the perfect calibration field for Galactic bulge studies. Aims. In the era of large spectroscopic surveys, calibration fields such as BW are necessary for cross calibrating the stellar parameters and individual abundances of the APOGEE survey. Methods. We use the APOGEE BW stars to derive the metallicity distribution function (MDF) and individual abundances for alpha- and iron-peak elements of the APOGEE ASPCAP pipeline (DR13), as well as the age distribution for stars in BW. Results. We determine the MDF of APOGEE stars in BW and find a remarkable agreement with that of the Gaia-ESO survey (GES). Both exhibit a clear bimodal distribution. We also find that the Mg-metallicity planes of the two surveys agree well, except for the metal-rich part ([Fe/H] > 0.1), where APOGEE finds systematically higher Mg abundances with respect to the GES. The ages based on the [C/N] ratio reveal a bimodal age distribution, with a major old population at similar to 10 Gyr, with a decreasing tail towards younger stars. A comparison of stellar parameters determined by APOGEE and those determined by other sources reveals detectable systematic offsets, in particular for spectroscopic surface gravity estimates. In general, we find a good agreement between individual abundances of O,Na, Mg, Al, Si, K, Ca, Cr, Mn, Co, and Ni from APOGEE with that of literature values. Conclusions. We have shown that in general APOGEE data show a good agreement in terms of MDF and individual chemical abundances with respect to literature works. Using the [C/N] ratio we found a significant fraction of young stars in BW.
|
|
| 25. |
|
|
| 26. |
- Dai, F., et al.
(författare)
-
The Discovery and Mass Measurement of a New Ultra-short-period Planet: K2-131
- 2017
-
Ingår i: Astronomical Journal. - : American Astronomical Society. - 1538-3881 .- 0004-6256. ; 154:6, s. 226-
-
Tidskriftsartikel (refereegranskat)abstract
- We report the discovery of a new ultra-short-period planet and summarize the properties of all such planets for which the mass and radius have been measured. The new planet, EPIC 228732031b, was discovered in K2 Campaign 10. It has a radius of 1.81-0.12+0.16 R_Earth and orbits a G dwarf with a period of 8.9 hr. Radial velocities obtained with Magellan/PFS and TNG/HARPS-N show evidence for stellar activity along with orbital motion. We determined the planetary mass using two different methods: (1) the “floating chunk offset” method, based only on changes in velocity observed on the same night; and (2) a Gaussian process regression based on both the radial velocity and photometric time series. The results are consistent and lead to a mass measurement of 6.5+/- 1.6 M_Earth and a mean density of 6.0-2.7+3.0 g cm‑3.
|
|
| 27. |
- Darby, S, et al.
(författare)
-
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death : meta-analysis of individual patient data for 10,801 women in 17 randomised trials
- 2011
-
Ingår i: The Lancet. - 0140-6736 .- 1474-547X. ; 378:9804, s. 16-1707
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: After breast-conserving surgery, radiotherapy reduces recurrence and breast cancer death, but it may do so more for some groups of women than for others. We describe the absolute magnitude of these reductions according to various prognostic and other patient characteristics, and relate the absolute reduction in 15-year risk of breast cancer death to the absolute reduction in 10-year recurrence risk.METHODS: We undertook a meta-analysis of individual patient data for 10,801 women in 17 randomised trials of radiotherapy versus no radiotherapy after breast-conserving surgery, 8337 of whom had pathologically confirmed node-negative (pN0) or node-positive (pN+) disease.FINDINGS: Overall, radiotherapy reduced the 10-year risk of any (ie, locoregional or distant) first recurrence from 35·0% to 19·3% (absolute reduction 15·7%, 95% CI 13·7-17·7, 2p<0·00001) and reduced the 15-year risk of breast cancer death from 25·2% to 21·4% (absolute reduction 3·8%, 1·6-6·0, 2p=0·00005). In women with pN0 disease (n=7287), radiotherapy reduced these risks from 31·0% to 15·6% (absolute recurrence reduction 15·4%, 13·2-17·6, 2p<0·00001) and from 20·5% to 17·2% (absolute mortality reduction 3·3%, 0·8-5·8, 2p=0·005), respectively. In these women with pN0 disease, the absolute recurrence reduction varied according to age, grade, oestrogen-receptor status, tamoxifen use, and extent of surgery, and these characteristics were used to predict large (≥20%), intermediate (10-19%), or lower (<10%) absolute reductions in the 10-year recurrence risk. Absolute reductions in 15-year risk of breast cancer death in these three prediction categories were 7·8% (95% CI 3·1-12·5), 1·1% (-2·0 to 4·2), and 0·1% (-7·5 to 7·7) respectively (trend in absolute mortality reduction 2p=0·03). In the few women with pN+ disease (n=1050), radiotherapy reduced the 10-year recurrence risk from 63·7% to 42·5% (absolute reduction 21·2%, 95% CI 14·5-27·9, 2p<0·00001) and the 15-year risk of breast cancer death from 51·3% to 42·8% (absolute reduction 8·5%, 1·8-15·2, 2p=0·01). Overall, about one breast cancer death was avoided by year 15 for every four recurrences avoided by year 10, and the mortality reduction did not differ significantly from this overall relationship in any of the three prediction categories for pN0 disease or for pN+ disease.INTERPRETATION: After breast-conserving surgery, radiotherapy to the conserved breast halves the rate at which the disease recurs and reduces the breast cancer death rate by about a sixth. These proportional benefits vary little between different groups of women. By contrast, the absolute benefits from radiotherapy vary substantially according to the characteristics of the patient and they can be predicted at the time when treatment decisions need to be made.FUNDING: Cancer Research UK, British Heart Foundation, and UK Medical Research Council.
|
|
| 28. |
- Guenther, E. W., et al.
(författare)
-
K2-106, a system containing a metal-rich planet and a planet of lower density
- 2017
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 608, s. 93-
-
Tidskriftsartikel (refereegranskat)abstract
- Planets in the mass range from 2 to 15 M_Earth are very diverse. Some of them have low densities, while others are very dense. By measuring the masses and radii, the mean densities, structure, and composition of the planets are constrained. These parameters also give us important information about their formation and evolution, and about possible processes for atmospheric loss.We determined the masses, radii, and mean densities for the two transiting planets orbiting K2-106. The inner planet has an ultra-short period of 0.57 days. The period of the outer planet is 13.3 days. Although the two planets have similar masses, their densities are very different. For K2-106b we derive Mb=8.36-0.94+0.96 M_Earh, Rb=1.52+/-0.16 R_Earth, and a high density of 13.1-3.6+5.4 g/cm^3. For K2-106c, we find Mc=5.8-3.0+3.3 M_Earth, Rc=2.50-0.26+0.27 R_Earth and a relatively low density of 2.0-1.1+1.6 g/cm^3.Since the system contains two planets of almost the same mass, but different distances from the host star, it is an excellent laboratory to study atmospheric escape. In agreement with the theory of atmospheric-loss processes, it is likely that the outer planet has a hydrogen-dominated atmosphere. The mass and radius of the inner planet is in agreement with theoretical models predicting an iron core containing 80+20-30% of its mass. Such a high metal content is surprising, particularly given that the star has an ordinary (solar) metal abundance. We discuss various possible formation scenarios for this unusual planet.
|
|
| 29. |
|
|
| 30. |
|
|
| 31. |
|
|
| 32. |
- Akiyama, Kazunori, et al.
(författare)
-
First Sagittarius A* Event Horizon Telescope Results. II. EHT and Multiwavelength Observations, Data Processing, and Calibration
- 2022
-
Ingår i: Astrophysical Journal Letters. - : American Astronomical Society. - 2041-8213 .- 2041-8205. ; 930:2
-
Tidskriftsartikel (refereegranskat)abstract
- We present Event Horizon Telescope (EHT) 1.3 mm measurements of the radio source located at the position of the supermassive black hole Sagittarius A* (Sgr A*), collected during the 2017 April 5-11 campaign. The observations were carried out with eight facilities at six locations across the globe. Novel calibration methods are employed to account for Sgr A*'s flux variability. The majority of the 1.3 mm emission arises from horizon scales, where intrinsic structural source variability is detected on timescales of minutes to hours. The effects of interstellar scattering on the image and its variability are found to be subdominant to intrinsic source structure. The calibrated visibility amplitudes, particularly the locations of the visibility minima, are broadly consistent with a blurred ring with a diameter of similar to 50 mu as, as determined in later works in this series. Contemporaneous multiwavelength monitoring of Sgr A* was performed at 22, 43, and 86 GHz and at near-infrared and X-ray wavelengths. Several X-ray flares from Sgr A* are detected by Chandra, one at low significance jointly with Swift on 2017 April 7 and the other at higher significance jointly with NuSTAR on 2017 April 11. The brighter April 11 flare is not observed simultaneously by the EHT but is followed by a significant increase in millimeter flux variability immediately after the X-ray outburst, indicating a likely connection in the emission physics near the event horizon. We compare Sgr A*'s broadband flux during the EHT campaign to its historical spectral energy distribution and find that both the quiescent emission and flare emission are consistent with its long-term behavior.
|
|
| 33. |
|
|
| 34. |
|
|
| 35. |
|
|
| 36. |
|
|
| 37. |
- Rojas-Arriagada, A., et al.
(författare)
-
The Gaia-ESO Survey: metallicity and kinematic trends in the Milky Way bulge
- 2014
-
Ingår i: Astronomy & Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 569
-
Tidskriftsartikel (refereegranskat)abstract
- Aims. Observational studies of the Milky Way bulge are providing increasing evidence of its complex chemo-dynamical patterns and morphology. Our intent is to use the iDR1 Gaia-ESO Survey (GES) data set to provide new constraints on the metallicity and kinematic trends of the Galactic bulge, exploring the viability of the currently proposed formation scenarios. Methods. We analyzed the stellar parameters and radial velocities of similar to 1200 stars in five bulge fields wich are located in the region -10 degrees < / < 7 degrees and -10 degrees < b < -4 degrees. We use VISTA Variables in the Via Lactea (VVV) photometry to verify the internal consistency of the atmospheric parameters recommended by the consortium. As a by-product, we obtained reddening values using a semi-empirical Tdf -color calibration. We constructed the metallicity distribution functions and combined them with photometric and radial velocity data to analyze the properties of the stellar populations in the observed fields. Results. From a Gaussian decomposition of the metallicity distribution functions, we unveil a clear bimodality in all fields, with the relative size of components depending of the specific position on the sky. In agreement with some previous studies, we find a mild gradient along the minor axis (-0.05 dex/deg between b = -6 degrees and b = -10 degrees) that arises from the varying proportion of metal-rich and metal-poor components. The number of metal-rich stars fades in favor of the metal-poor stars with increasing b. The K-magnitude distribution of the metal-rich population splits into two peaks for two of the analyzed fields that intersects the near and far branches of the X-shaped bulge structure. In addition, two lateral fields at (l,b) = (7, -9) and (l, b) = (-10, 8) present contrasting characteristics. In the former, the metallicity distribution is dominated by metal-rich stars, while in the latter it presents a mix of a metal-poor population and and a metal-intermediate one, of nearly equal sizes. Finally, we find systematic differences in the velocity dispersion between the metal-rich and the metal-poor components of each field. Conclusions. The iDR I bulge data show chemo-dynamical distributions that are consistent with varying proportions of stars belonging to (i) a metal-rich boxy/peanut X-shaped component, with bar-like kinematics; and (ii) a metal-poor more extended rotating structure with a higher velocity dispersion that dominates far from the Galactic plane. These first GES data already allow studying the detailed spatial dependence of the Galactic bulge populations, thanks to the analysis of individual fields with relatively high statistics.
|
|
| 38. |
- Schultheis, M., et al.
(författare)
-
The nuclear stellar disc of the Milky Way : A dynamically cool and metal-rich component possibly formed from the central molecular zone
- 2021
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 650
-
Tidskriftsartikel (refereegranskat)abstract
- Context. The nuclear stellar disc (NSD) is, together with the nuclear star cluster (NSC) and the central massive black hole, one of the main components in the central parts of our Milky Way. However, until recently, only a few studies of the stellar content of the NSD have been obtained owing to extreme extinction and stellar crowding. Aims. We study the kinematics and global metallicities of the NSD based on the observations of K/M giant stars via a dedicated KMOS (VLT, ESO) spectroscopic survey. Methods. We traced radial velocities and metallicities, which were derived based on spectral indices (Na I and CO) along the NSD, and compared those with a Galactic bulge sample of APOGEE (DR16) and data from the NSC. Results. We find that the metallicity distribution function and the fraction of metal-rich and metal-poor stars in the NSD are different from the corresponding distributions and ratios of the NSC and the Galactic bulge. By tracing the velocity dispersion as a function of metallicity, we clearly see that the NSD is kinematically cool and that the velocity dispersion decreases with increasing metallicity contrary to the inner bulge sample of APOGEE (|b|< 4°). Using molecular gas tracers (H2CO, CO(4-3)) of the central molecular zone (CMZ), we find an astonishing agreement between the gas rotation and the rotation of the metal-rich population. This agreement indicates that the metal-rich stars could have formed from gas in the CMZ. On the other hand, the metal-poor stars show a much slower rotation profile with signs of counter-rotation, thereby indicating that these stars have a different origin. Conclusions. Coupling kinematics with global metallicities, our results demonstrate that the NSD is chemically and kinematically distinct with respect to the inner bulge, which indicates a different formation scenario.
|
|
| 39. |
|
|
| 40. |
|
|
| 41. |
|
|
| 42. |
|
|
| 43. |
- Arriagada, R., et al.
(författare)
-
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
- 2004
-
Ingår i: N Engl J Med. ; 350:4
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: On the basis of a previous meta-analysis, the International Adjuvant Lung Cancer Trial was designed to evaluate the effect of cisplatin-based adjuvant chemotherapy on survival after complete resection of non-small-cell lung cancer. METHODS: We randomly assigned patients either to three or four cycles of cisplatin-based chemotherapy or to observation. Before randomization, each center determined the pathological stages to include, its policy for chemotherapy (the dose of cisplatin and the drug to be combined with cisplatin), and its postoperative radiotherapy policy. The main end point was overall survival. RESULTS: A total of 1867 patients underwent randomization; 36.5 percent had pathological stage I disease, 24.2 percent stage II, and 39.3 percent stage III. The drug allocated with cisplatin was etoposide in 56.5 percent of patients, vinorelbine in 26.8 percent, vinblastine in 11.0 percent, and vindesine in 5.8 percent. Of the 932 patients assigned to chemotherapy, 73.8 percent received at least 240 mg of cisplatin per square meter of body-surface area. The median duration of follow-up was 56 months. Patients assigned to chemotherapy had a significantly higher survival rate than those assigned to observation (44.5 percent vs. 40.4 percent at five years [469 deaths vs. 504]; hazard ratio for death, 0.86; 95 percent confidence interval, 0.76 to 0.98; P<0.03). Patients assigned to chemotherapy also had a significantly higher disease-free survival rate than those assigned to observation (39.4 percent vs. 34.3 percent at five years [518 events vs. 577]; hazard ratio, 0.83; 95 percent confidence interval, 0.74 to 0.94; P<0.003). There were no significant interactions with prespecified factors. Seven patients (0.8 percent) died of chemotherapy-induced toxic effects. CONCLUSIONS: Cisplatin-based adjuvant chemotherapy improves survival among patients with completely resected non-small-cell lung cancer.
|
|
| 44. |
|
|
| 45. |
|
|
| 46. |
- Arriagada, R, et al.
(författare)
-
Effect of radiation dose on local control in breast cancer
- 2008
-
Ingår i: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. - : Elsevier BV. - 0167-8140. ; 86:2, s. 285-286
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 47. |
|
|
| 48. |
|
|
| 49. |
|
|
| 50. |
|
|
